August 2017 Issue of The Medicine Maker

In 100 years, medicine is likely to be vastly different to what we can predict – or even imagine.

Can cell and gene therapies paint a picture of perfect future health?

Multistep continuous-flow manufacturing is easier said than done. But Eli Lilly has found a way…

Will pharma adopt distributed ledger technology for data management within the next five years?

The FDA aims to reduce drug prices with a more competitive market - and generics are key.

High-throughput excipient discovery looks set to boost oral bioavailability.

A small-molecule drug has shown its ability to diminish HIV reservoirs.

Joint letter from eight trade associations warns of “supply disruptions to life-saving medicines.”

Raymond Sackler, philanthropist, psychopharmacology pioneer, and former CEO of Purdue Pharma, dies aged 97.

A consortium aims to tackle cardiovascular disease with cell therapies

If pharma wants to adopt continuous manufacturing, it must employ control procedures to ensure quality.

Are you compliant with the new guidelines for elemental impurities? There’s only six months left to get up to speed.

The potential of inhaled drug delivery goes beyond traditional respiratory medicine.

Proposed cuts to the funding of US scientific agencies will be detrimental to global health.

Beyond developing medicines, what is the pharma industry doing to help make the world a better place?

When looking to do good, many companies choose to focus on children’s health, particularly in developing countries.

The first principal of corporate social responsibility is to improve lives – but goodwill and positivity are infectious.

Steve Davis details some of the PATH's success stories in global health.

Sustainable contracts and more subtle efforts can also go a long way to helping others worldwide.

Pharmaceutical firms are some of the most generous, in terms of their philanthropy.

"Collaboration – across sectors, governments and communities – is the key to effective social endeavors."

Big Pharma can impact millions of lives, but charity on a smaller scale also makes a difference.

According to novo Nordisk, being a good corporate citizen is simply “the right thing to do."

Why stop at biosimilar when you can be biobetter?

Can enzyme immobilization enhance biocatalysis further?

Each new drug is unique and deserves a fresh approach to formulation.

Steve Davis, President and CEO of PATH, and lecturer, Social Innovation, at Stanford University, California, USA.

With approximately 80 percent of new drugs suffering from poor solubility and bioavailability, understanding solid form is more important than ever.

Tracing the supply chain back to raw materials and learning how fundamental research is driving advances in cell culture media.

A handful of cell- and gene-based therapies have now been approved, and more are sure to follow.

We need to stop companies from using loopholes to sell unproven cell therapies to desperate patients

To effectively develop advanced therapies, you need the right supply chain management

In the growing field of advanced therapies, it's important to stick out from the crowd

As fast as gene therapies are progessing, there's still one major hurdle to overcome: cost

Five gurus discuss the exciting developments in advanced medicine, and what the field needs to move forward.

When it comes to cryopreserving cell therapies, there's a right way - and a wrong way…

Sitting down with Steve Oh from the Stem Cell Bioprocessing, Bioprocessing Technology Institute, A*STAR